GlassScriptPhysician profile
Aubrie Bird
NPI 1780454116
$1,053.32
in general payments reported to CMS, 2019-2025
24 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $462 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $162.16 | 2024-2025 | |
| Novo Nordisk INC | $161.68 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $113.19 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Saluda Medical Americas, INC. | $77.82 | 2025 | Evoke |
| Organon LLC | $63.47 | 2024 | |
| Astellas Pharma US INC | $47.50 | 2025 | Veozah |
| Pfizer INC. | $46.83 | 2024-2025 | |
| Hologic Sales and Service, LLC | $43.48 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $42.62 | 2024 | |
| Merck Sharp & Dohme LLC | $34.98 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $29.40 | 2025 | |
| Neos Therapeutics, LP | $28.43 | 2024 | Adzenys Xr-Odt |
| Boston Scientific Corporation | $23.45 | 2025 | Watchman Flx |
| Spr Therapeutics, INC | $22.71 | 2024 | Sprint Pns System |
| Seqirus USA INC | $20.54 | 2025 | Flucelvax, Fluad |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $17.67 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $17.54 | 2024 | Auvelity |
| Amneal Pharmaceuticals LLC | $16.91 | 2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $14.72 | 2024 | Airsupra |
| Exact Sciences Corporation | $14.07 | 2025 | The Cologuard Plus Collection Kit |
| Insulet Corporation | $13.98 | 2025 | Omnipod |
| Amgen INC. | $13.52 | 2024 | Otezla, Repatha |
| Biogen, INC. | $13.50 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.15 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aubrie Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.